register

News & Trends - MedTech & Diagnostics

World-first 3D imaging incorporates AI to revolutionise melanoma detection in Australia

Health Industry Hub | September 15, 2021 |

MedTech News: Queenslanders could have skin cancer diagnosed earlier using world-first 3D scanning technology with the launch of the Australian Cancer Research Foundation’s (ACRF) Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID).

University of Queensland Dermatologist Professor H. Peter Soyer said the technology enabled researchers to track moles and skin spots over time using full body mapping, making it a game-changer for melanoma detection.

“This technology is revolutionising early melanoma detection using 3D state-of-the-art body imaging systems that take an image in milliseconds,” Professor Soyer said.

“The telemedicine network allows dermatologists and medical professionals to detect skin cancers remotely, even from the other side of the country.

“For the first time, medical researchers can access a national database of up to 100,000 patient images taken by 3D full body imaging systems located in QLD, NSW and VIC, as part of the world’s largest melanoma imaging trial, which aims to develop more efficient and effective screening for the early detection of skin cancer.

“Using algorithms created by artificial intelligence (AI), the 3D imaging systems are able to analyse the images and produce a full body skin spot map, which transforms the way we will monitor patients in the future.”

Australia has the highest rates of melanoma in the world with an average 28,000 Australians diagnosed with the disease every year.

ACRF chief executive officer Kerry Strydom said the Australian Cancer Research Foundation backed the best in research and cutting-edge technology to drive innovation and help create the new Centre.

“Melanoma is a deadly problem that needs disruptive solutions, and ACRF is proud to be to be involved in delivering revolutionary research through this pioneering program,” Mr Strydom said.

The project brings together three leading Australian universities in skin research, UQ, University of Sydney and Melbourne’s Monash University, to form the interconnected Centre of Excellence in Diagnostic Imaging of Early Melanoma.

Queenslanders can sign up here to be part of the world’s largest melanoma imaging trial using the 3D full body imaging system located at Brisbane’s Princess Alexandra Hospital.

The 3D technology is expected to be rolled out to five other regions across Queensland.


News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines

Health Industry Hub | March 14, 2025 |

Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]

More


News & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug

Astellas secures new indication for prostate cancer drug

Health Industry Hub | March 14, 2025 |

Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]

More


News & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban

Stakeholder calls intensify as government stalls on genetic discrimination ban

Health Industry Hub | March 14, 2025 |

Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]

More


News & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day

Health Industry Hub | March 13, 2025 |

As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]

More


This content is copyright protected. Please subscribe to gain access.